Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Shirley Gek-Kheng Seah"'
Autor:
Biruhalem Taye, Hui Chen, Dawn Su-Yin Yeo, Shirley Gek-Kheng Seah, Michelle Su-Yen Wong, Richard J Sugrue, Boon-Huan Tan
Publikováno v:
Cells, Vol 9, Iss 2, p 448 (2020)
Although the influenza A virus H7N9 subtype circulates within several avian species, it can also infect humans with a severe disease outcome. To better understand the biology of the H7N9 virus we examined the host response to infection in avian and h
Externí odkaz:
https://doaj.org/article/7b4eba4e07cb45d4beb0e9bfc088259c
Autor:
Agata Blasiak, Anh T. L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T. P. Lin, David C. B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, Dean Ho
Publikováno v:
npj Digital Medicine, Vol 5, Iss 1, Pp 1-12 (2022)
Abstract IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a
Externí odkaz:
https://doaj.org/article/523937a2d0914dc491cce1f3ee4e42c6
Autor:
Agata Blasiak, Jhin Jieh Lim, Shirley Gek Kheng Seah, Theodore Kee, Alexandria Remus, De Hoe Chye, Pui San Wong, Lissa Hooi, Anh T. L. Truong, Nguyen Le, Conrad E. Z. Chan, Rishi Desai, Xianting Ding, Brendon J. Hanson, Edward Kai‐Hua Chow, Dean Ho
Publikováno v:
Bioengineering & Translational Medicine, Vol 6, Iss 1, Pp n/a-n/a (2021)
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that
Externí odkaz:
https://doaj.org/article/3bdb703644b14f66b5677f820eca6cec
Autor:
Agata Blasiak, Anh T. L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T. P. Lin, David C. B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, Dean Ho
Publikováno v:
NPJ digital medicine. 5(1)
IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d29235d08a7df65af2d238d72595e2b
https://pubmed.ncbi.nlm.nih.gov/35773329
https://pubmed.ncbi.nlm.nih.gov/35773329
Autor:
David M Allen, Gek-Yen Gladys Tan, Peter Wang, Alexandria Remus, Anh T. L. Truong, Yee-Joo Tan, Raymond T. P. Lin, Agata Blasiak, Edward Kai-Hua Chow, Wee Joo Chng, Kim Tien Ng, Angeline Pei Chiew Lim, Louis Yi Ann Chai, De Hoe Chye, Dean Ho, John Wong, Conrad E.Z. Chan, David C. Lye, Swee Teng Teo, Shirley Gek Kheng Seah, Lissa Hooi
ObjectivesWe aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19.MethodsA pool of starting candidate therapies was developed in collaboration wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3657e0b9e1d56a1030e8d79de9129c4c
https://doi.org/10.1101/2021.06.23.21259321
https://doi.org/10.1101/2021.06.23.21259321
Autor:
Bei Wang, Daniel Asarnow, Wen-Hsin Lee, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus Bohn, David Bulkley, Andrés Pizzorno, Hwee Ching Tan, Chia Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek Kheng Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
In vitro antibody selection against pathogens from naïve combinatorial libraries can yield various classes of antigen-specific binders that are distinct from those evolved from natural infection1–4. Also, rapid neutralizing antibody discovery can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38885bd9bef5c4aadb645f8ff2e2baf
https://hal.science/hal-02988332/file/2020.07.14.203414v1.full.pdf
https://hal.science/hal-02988332/file/2020.07.14.203414v1.full.pdf
Autor:
Chien-Te K Tseng, Dipti Thakkar, Boyd-Kirkup Jerome Douglas, Trevor Brasel, Paul A. MacAry, Dong Ling Wang, Jason E. Comer, Hannes Hentze, Ingram Piers, Brendon J. Hanson, Angeline P.C. Lim, Guan Siyu, Maricela Torres, Kiren Purushotorman, Damian O’Connell, Jacklyn J.Y. Neo, Guo Hui Teo, Steven K.K. Wong, Conrad E.Z. Chan, Shirley Gek Kheng Seah, Venkateshan S. Prativadibhayankara, Paul Edward Hutchinson, De Hoe Chye, Jenny G. Low, Gary S.L. Loh, Kantharaj Ethirajulu, David C. Lye, Jie Hui Lim, Pui San Wong, Barnaby Edward Young, Alan D.T. Barrett, Shane Massey
SARS-CoV-2-neutralizing antibodies are promising therapeutics for COVID-19. However, little is known about the mechanisms of action of these antibodies or their effective dosing windows. We report the discovery and development of SC31, a potent SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::606850ac3cb09b13cecd9961dbe2c00e
https://doi.org/10.1101/2020.10.26.355107
https://doi.org/10.1101/2020.10.26.355107
Autor:
Conrad Chan, Lissa Hooi, Anh T. L. Truong, De Hoe Chye, Theodore Kee, Alexandria Remus, Jhin Jieh Lim, Brendon John Hanson, Dean Ho, Agata Blasiak, Edward Kai-Hua Chow, Nguyen Le, Shirley Gek Kheng Seah, Rishi J. Desai, Xianting Ding, Pui San Wong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3ef8d19f25241f8120e33ad936b2815
https://doi.org/10.1002/btm2.10196/v2/response1
https://doi.org/10.1002/btm2.10196/v2/response1
Autor:
Edward Kai-Hua Chow, Theodore Kee, De Hoe Chye, Lissa Hooi, Dean Ho, Nguyen Le, Shirley Gek Kheng Seah, Xianting Ding, Rishi J. Desai, Pui San Wong, Alexandria Remus, Brendon J. Hanson, Jhin Jieh Lim, Agata Blasiak, Anh T. L. Truong, Conrad E.Z. Chan
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) has led to the rapid initiation of urgently needed clinical trials of repurposed drug combinations and monotherapies. These regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2567ef110059affc2d73c8007fff9239
https://doi.org/10.1101/2020.05.04.20088104
https://doi.org/10.1101/2020.05.04.20088104
Autor:
Jie Hui Lim, Pui San Wong, Steven K.K. Wong, Chien Te K. Tseng, Guan Siyu, Paul A. MacAry, Shane Massey, Shirley Gek Kheng Seah, Alan D.T. Barrett, Dipti Thakkar, Jenny G. Low, Guo Hui Teo, Kantharaj Ethirajulu, Jason E. Comer, Brendon J. Hanson, Boyd-Kirkup Jerome Douglas, Ingram Piers, Venkateshan S. Prativadibhayankara, Barnaby Edward Young, Trevor Brasel, Angeline P.C. Lim, Hannes Hentze, Maricela Torres, Dongling Wang, Kiren Purushotorman, Jacklyn J.Y. Neo, Conrad E.Z. Chan, De Hoe Chye, Paul Edward Hutchinson, Gary S.L. Loh
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0253487 (2021)
PLoS ONE
PLoS ONE
Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-19, little is known about their mechanism(s) of action or effective dosing windows. We report the generation and development of SC31, a potent SARS-CoV-2 neutralizin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b552438306ce977645ca8b0816814c54
https://doi.org/10.1371/journal.pone.0253487
https://doi.org/10.1371/journal.pone.0253487